Discussion
A U.S.-based biotech company announced that it has reached a “significant” milestone in advancing its experimental stem cell treatment for recessive dystrophic epidermolysis bullosa (RDEB), a rare condition marked by extremely fragile skin. Inmune Bio said it has readied its process for commercial-grade manufacturing of CORDStrom, the stem…